Rotarix®: Vaccine performance 6 years postlicensure

Expert Review of Vaccines

Volumn 10, Issue 12, 2011, Pages 1645-1659

  O'Ryan, Miguel ^a,b   Lucero, Yalda ^a   Linhares, Alexandre C ^c  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c MINISTÉRIO DA SAÚDE   (Brazil)

Author keywords

children; diarrhea; effectiveness; gastroenteritis; genotype; human attenuated; intussusception; Rotarix ; rotavirus; safety; vaccine

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE;

ACUTE GASTROENTERITIS; ARTICLE; AUSTRALIA; BELGIUM; BRAZIL; CHILD; CIRCOVIRUS; DRUG APPROVAL; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; EPIDEMIC; GENOTYPE; HUMAN; PORTUGAL; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; ROTAVIRUS; ROTAVIRUS INFECTION; SEROTYPE; VIRUS STRAIN;

CHILD; DIARRHEA; DISEASE OUTBREAKS; GENOTYPE; GEOGRAPHY; HUMANS; IMMUNIZATION PROGRAMS; PRODUCT SURVEILLANCE, POSTMARKETING; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; TREATMENT OUTCOME; VACCINATION; VACCINES, ATTENUATED; WORLD HEALTH;

EID: 81355122723     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.152     Document Type: Article

References (67)

1. O'Ryan M, Linhares AC. Update on rotarix: an oral human rotavirus vaccine. Expert Rev. Vaccines 8(12), 1627-1641 (2009).
2. Vesikari T, Karvonen A, Prymula R et al. Efficacy of human rotavirus vaccine against Rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 370, 1757-1763 (2007). (Pubitemid 350137490)
3. Phua KB, Lim FS, Lau YL et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine 27, 5936-5941 (2009).
4. Linhares AC, Velázquez FR, Pérez-Schael I et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo controlled Phase 3 study. Lancet 371, 1181-1189 (2008). (Pubitemid 351458523)
5. Tregnaghi MW, Abate HJ, Valencia A et al. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr. Infect. Dis. J. 30, e103-e108 (2011).
6. Madhi SA, Cunliffe NA, Steele D et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N. Engl. J. Med. 362, 289-298 (2010).
7. Steele AD, Madhi SA, Louw CE et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatr. Infect. Dis. J. 30, 25-30 (2011).
8. Kawamura N, Tokoeda Y, Oshima M et al. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine 29, 6335-6341 (2011).
9. World Health Organization. Meeting of the immunization strategic advisory group of experts, April 2009 - conclusions and recommendations. Wkly Epidemiol. Rec. 84, 13-236 (2009).
10. Parry J. New vaccines to boost child care in developing countries. World Health Organ. 85, 426-427 (2007).
11. You D, Wardlaw T, Salama P, Jones G. Levels and trends in under-5 mortality, 1990-2008. Lancet 375, 100-103 (2010).
12. Patel MM, Steele, D, Gentsch JR et al. Real-world impact of rotavirus vaccination. Pediatr. Infect. Dis. J. 30(Suppl. 1), S1-S5 (2011).
13. De Oliveira LH, Donovaro-Holliday MC, Mattus CR, Andrus JK. Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert Rev. Vaccines 7, 345-353 (2008). (Pubitemid 351520022)
14. Tate JE, Patel MM, Steele AD et al. Global impact of rotavirus vaccines. Expert Rev. Vaccines 9, 395-407 (2010).
15. Usher AD. GAVI takes steps to address funding woes. Lancet 377, 453 (2011).
16. Patel MM, Parashar UD. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs. J. Infect. Dis. 200(Suppl. 1), S291-S299 (2009).
17. Patel MM, López-Collada VR, Bulhões MM et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N. Engl. J. Med. 364, 2283-2292 (2011).
18. De Palma O, Cruz L, Ramos H et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ 340, c2825 (2010).
19. Correia JB, Patel MM, Nakagomi O et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhoea caused by serotypically-unrelated G2P[4] strains in Brazil. J. Infect. Dis. 201, 363-369 (2010).
20. Justino MCA, Linhares AC, Lanzieri R et al. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil. Pediatr. Infect. Dis. J. 30, 396-401 (2011).
21. Snelling TL, Schultz R, Graham J et al. Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. CID 49, 428-431 (2009).
22. Snelling TL, Andrews RM, Kirkwood CM et al. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in Central Australia. CID 52, 191-199 (2011).
23. Zeller M, Rahman M, Heylen E et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 28, 7507-7513 (2010).
24. Braeckman T, Van Herck K, Raes M et al. Rotavirus vaccines in Belgium: policy and impact. Pediatr. Infect. Dis. J. 30(Suppl. 1), S21-S24 (2011).
25. Paulke-Korinek M, Rendi-Wagner P, Kundi M, Kronik R, Kollaritsch H. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children. Pediatr. Infect. Dis. J. 29, 319-323 (2010).
26. Buttery JP, Lambert SB, Grimwood K et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's national childhood vaccine schedule. Pediatr. Infect. Dis. J. 30(Suppl. 1), S25-S29 (2011).
27. Macartney KK, Porwal M, Dalton D et al. Decline in rotavirus hospitalisations following introduction of Australia's national rotavirus immunisation programme. J. Paediatr. Child Health 47, 266-270 (2011).
28. Molto Y, Cortes JE, De Oliveira LH et al. Reduction of diarrhea-associated hospitalizations among children aged < 5 years in panama following the introduction of rotavirus vaccine Pediatr. Infect. Dis. J. 30 1 S16-S20 2011
29. Quintanar-Solares M, Yen C, Richardson V et al.Impact of rotavirus vaccination on diarrhea-related hospitalizations among children <5 years of age in Mexico. Pediatr.Infect. Dis. J. 30(Suppl. 1), S11-S15 (2011).
30. Yen C, Armero Guardado JA, Alberto P et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea ollowing rotavirus vaccination in El Salvador. Pediatr. Infect. Dis. J. 30(Suppl. 1), S6-S10 (2011).
31. Gurgel RQ, Bohland AN, Vieira SA et al. Incidence of rotavirus and all-cause diarrhea in northeast Brazil following the introduction of a national vaccination program. Gastroenterology 137, 1970-1975 (2009).
32. Sáfadi MA, Berezin EN, Munford V et al. Hospital-based surveillance to evaluate the impact of rotavirus vaccination in São Paulo, Brazil. Pediatr. Infect. Dis. J. 29, 1019-1022 (2010).
33. Lanzieri T, Costa I, Shafi F et al. Trends in hospitalizations from all-cause gastroenteritis in children younger than 5 years of age in Brazil before and after human rotavirus vaccine introduction, 1998-2007. Pediatr. Infect. Dis. J. 29, 673-675 (2010).
34. Do Carmo GM, Yen C, Cortes J et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med. 8, e1001024 (2011).
35. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N. Engl. J. Med. 362, 299-305 (2010).
36. Lanzieri TM, Linhares AC, Costa I et al. Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil. Int. J. Infect. Dis. 15, e206-e210 (2011).
37. Murphy TV, Gargiullo PM, Massoudi MS et al. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. 344, 564-572 (2001). (Pubitemid 32167870)
38. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med. 354, 11-22 (2006). (Pubitemid 43048947)
39. Vesikari T, Matson DO, Dennehy P et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 354, 23-33 (2006). (Pubitemid 43048948)
40. Macias M. The rotavirus vaccine RIX 4414 (Rotarix) is not associated with intussusception in one year old infants. ICAAC, Washington, DC, USA (2005).
41. Greenberg HB. Rotavirus vaccination and intussusceptions - act two. N. Engl. J. Med. 364, 2354-2355 (2011).
42. Buttery JP, Danchin MH, Lee KJ et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the national immunization program in Australia. Vaccine 29, 3061-3066 (2011).
43. Velazquez R. PP106. Special issue: abstracts from the 2nd excellence in paediatrics conference, 2-4 Dec 2010, London, UK. Acta Paediatrica 99(Suppl. 462), 47-120 (2010).
44. Haber P, Patel M, Izurieta HS et al. Post licensure monitoring of intussusception after RotaTeq vaccination in the United States, 1 February 2006-2025 September 2007. Pediatrics 121, 1206-1212 (2008).
45. O'Ryan M. The ever-changing landscape of rotavirus serotypes. Pediatr. Infect. Dis. J. 28, S60-S62 (2009).
46. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev. Med. Virol. 15, 29-56 (2005). (Pubitemid 40070041)
47. Gentsch JR, Parashar UD, Glass RI. Impact of rotavirus vaccination: the importance of monitoring strains. Fut. Microbiol. 4, 1231-1234 (2009).
48. Matthijnssens J, Bilcke J, Ciarlet M et al. Rotavirus disease and vaccination: impact on genotype diversity. Fut. Microbiol. 4, 1303-1316 (2009).
49. Gurgel RQ, Cuevas LE, Vieira SC et al. Predominance of rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg. Infect. Dis. 13, 1571-1573 (2007). (Pubitemid 350006998)
50. Gurgel RQ, Correia JB, Cuevas LE. Effect of rotavirus vaccination on circulating virus strains. Lancet 371, 301-302 (2008). (Pubitemid 351754783)
51. Nakagomi T, Cuevas LE, Gurgel RQ et al. Apparent extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after the introduction of rotavirus vaccine. Arch. Virol. 153, 591-593 (2008).
52. Leite JP, Carvalho-Costa FA, Linhares AC. Group A rotavirus genotypes and the ongoing Brazilian experience - a review. Mem. Inst. Oswaldo Cruz 103, 745-753 (2008).
53. Carvalho-Costa FA, Araújo IT, de Assis RMS et al. Rotavirus genotype distribution after vaccine introduction, Rio de Janeiro, Brazil. Emerg. Infect. Dis. 15, 95-97 (2009).
54. Morillo SG, Luchs A, Cilli A et al. Characterization of rotavirus strains from day care centers: pre- and post-rotavirus vaccine era. J. Pediatr. 86, 155-158 (2010).
55. Carvalho-Costa FA, Volotão EM, de Assis RMS et al. Laboratory-based rotavirus surveillance during the introduction of a vaccination program, Brazil, 2005-2009. Pediatr. Infect. Dis. J. 30, S35-S41 (2011).
56. Rodrigues F, Iturriza M, Gonçalves G et al. Large variations in rotavirus (RV) disease and strain diversity during low-level vaccine use in Portugal. Presented at: 28th Annual Meeting of the European Society of Paediatric Infectious Diseases. Nice, France, 4-8 May 2010.
57. Kirkwood CD, Boniface K, Barnes GL et al. Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix and RotaTeq, into the national immunization program of Australia. Pediatr. Infect. Dis. J. 30, S48-S53 (2011).
58. Linhares AC, Stupka JA, Ciapponi A et al. Burden and typing of rotavirus group A in Latin America and the Caribbean: systematic review and meta-analysis. Rev. Med. Virol. doi:10.1002/rmv.682 (2011) (Epub ahead of print).
59. Linhares AC, Velázquez FR. Rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg. Infect. Dis. 14, 863-865 (2008).
60. Esteban LE, Rota LP, Gentsch JR et al. Molecular epidemiology of group A rotavirus in Buenos Aires, Argentina 2004-2007: reemergence of G2P[4] and emergence of G9P[8] strains. J. Med. Virol. 82, 1083-1093 (2010).
61. Patel M, Pedreira C, De Oliveira LH et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 301, 2243-2251 (2009).
62. De Vos B, Han HH, Bouckenooghe A et al. Live attenuated rotavirus vaccine RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes. Pediatr. Infect. Dis. J. 28, 261-266 (2009).
63. Victoria JG, Wang C, Jones MS et al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J. Virol. 84, 6033-6040 (2010).
64. Kuehn B. FDA: Benefits of rotavirus vaccination outweigh potential contamination risk. JAMA 304, 30-31 (2010).
65. Baylis SA, Finsterbusch T, Bannert N, Blümel J, Mankertz A. Analysis of porcine circovirus type 1 detected in Rotarix vaccine. Vaccine 29, 690-697 (2011).
66. Alejandro MB, Domingo JD, Martinón- Torres F. Circovirus and impact of temporary withdrawal of rotavirus vaccines in Spain. Hum. Vaccines 7, 798-799 (2011).
67. Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J. Infect. Dis. 204, 980-986 (2011).